A UNIQUELY SCALABLE PLATFORM FOR SEQUENCING TENS OF MILLIONS OF SINGLE CELLS FROM COMPLEX CLINICAL SAMPLES WITH A STREAMLINED WORKFLOW - PROJECT SUMMARY/ABSTRACT SINGLE-CELL SEQUENCING (SC-SEQ) HAS REVOLUTIONIZED OUR UNDERSTANDING OF CELLULAR HETEROGENEITY, GENE EXPRESSION, AND DISEASE MECHANISMS. HOWEVER, ITS ADOPTION IN CLINICAL AND TRANSLATIONAL RESEARCH REMAINS LIMITED DUE TO THROUGHPUT CONSTRAINTS, COMPLEX WORKFLOWS, AND SAMPLE PREPARATION BIASES. SANSIMEON IS ADDRESSING THESE LIMITATIONS BY DEVELOPING A HIGH- THROUGHPUT, STREAMLINED PLATFORM FOR SCALABLE SINGLE-CELL SEQUENCING. THIS INNOVATIVE SYSTEM INTEGRATES AUTOMATED WORKFLOW FOR DIRECT ANALYSIS OF PERIPHERAL WHOLE BLOOD AND DISSOCIATED TISSUE. OUR GOAL IS TO DELIVER AN END-TO-END SOLUTION CAPABLE OF PROCESSING LARGE-SCALE SINGLE CELL EXPERIMENTS, WITH APPLICATIONS IN DIAGNOSTICS, RARE CELL DETECTION, DRUG DISCOVERY, AND CANCER THERAPY DEVELOPMENT. WE LEVERAGE NOVEL MICROFLUIDIC TECHNOLOGIES TO ACHIEVE UNMATCHED THROUGHPUT AND DATA FIDELITY WHILE PRESERVING CELLS' NATIVE STATES. THE PROJECT WILL VALIDATE THIS SYSTEM IN CLINICALLY RELEVANT SAMPLES AND OPTIMIZE ITS COMPUTATIONAL TOOLS TO SUPPORT SCALED SINGLE- CELL DATASETS. THESE EFFORTS AIM TO ADVANCE CLINICAL RESEARCH AND ACCELERATE THE ADOPTION OF SINGLE- CELL SEQUENCING IN HEALTHCARE AND DRUG DEVELOPMENT.